纳武利尤单抗联合伊匹木单抗一线治疗转移性非小细胞肺癌伴基线脑转移患者的全身与颅内结局:CheckMate 227 第1部分
CheckMate 227第1部分的事后探索性分析,在至少随访61.3个月时,评估基线脑转移状态对纳武利尤单抗联合伊匹木单抗一线治疗转移性NSCLC的全身和颅内疗效及安全性影响。伴基线脑转移患者中,联合组相比化疗延长OS(HR=0.63),5年全身和颅内PFS率更高,新发脑病灶更少。
要点
- 伴基线脑转移患者中,纳武利尤单抗联合伊匹木单抗较化疗延长OS(HR=0.63;95%CI:0.43-0.92)。
- 伴脑转移患者5年全身PFS率联合组12% vs 化疗组0%,颅内PFS率16% vs 6%。
- 伴脑转移患者新发脑病灶联合组4% vs 化疗组20%,未见新安全性信号。
核心结论
- 所有患者停用免疫治疗至少3年时,纳武利尤单抗联合伊匹木单抗在有或无脑转移患者中持续提供长期、持久的生存获益。
- 颅内疗效结局倾向于支持纳武利尤单抗联合伊匹木单抗优于化疗。
- 这些结果进一步支持纳武利尤单抗联合伊匹木单抗作为转移性NSCLC的有效一线治疗,无论基线脑转移状态如何。
研究设计与样本
- CheckMate 227第1部分的事后探索性分析,报告至少随访5年时按基线脑转移状态划分的全身和颅内疗效及安全性结局。
- 入组初治成人IV期或复发性NSCLC患者,无EGFR或ALK改变,包括无症状的经治脑转移患者。
- 肿瘤PD-L1≥1%的患者随机分配至纳武利尤单抗联合伊匹木单抗、纳武利尤单抗或化疗组;肿瘤PD-L1<1%的患者随机分配至纳武利尤单抗联合伊匹木单抗、纳武利尤单抗联合化疗或化疗组。
- 1739例随机患者中202例有基线脑转移(纳武利尤单抗联合伊匹木单抗组68例,化疗组66例)。
主要发现
- 在至少随访61.3个月时,伴基线脑转移患者中纳武利尤单抗联合伊匹木单抗较化疗延长OS(HR=0.63;95%CI:0.43-0.92),无基线脑转移患者中亦延长OS(HR=0.76;95%CI:0.66-0.87)。
- 伴基线脑转移患者中,纳武利尤单抗联合伊匹木单抗组5年全身无进展生存率为12%,化疗组为0%。
- 伴基线脑转移患者中,纳武利尤单抗联合伊匹木单抗组5年颅内无进展生存率为16%,化疗组为6%。
- 伴基线脑转移患者中,纳武利尤单抗联合伊匹木单抗组新发脑病灶发生率为4%,化疗组为20%。
- 未观察到新的安全性信号。
关键数值与推荐
- 伴基线脑转移患者中,纳武利尤单抗联合伊匹木单抗组OS的HR=0.63(95%CI:0.43-0.92)。
- 无基线脑转移患者中,纳武利尤单抗联合伊匹木单抗组OS的HR=0.76(95%CI:0.66-0.87)。
- 伴基线脑转移患者中,5年全身无进展生存率纳武利尤单抗联合伊匹木单抗组12% vs 化疗组0%。
- 伴基线脑转移患者中,5年颅内无进展生存率纳武利尤单抗联合伊匹木单抗组16% vs 化疗组6%。
- 伴基线脑转移患者中,新发脑病灶发生率纳武利尤单抗联合伊匹木单抗组4% vs 化疗组20%。
临床怎么用
- 对于转移性NSCLC伴基线脑转移患者,纳武利尤单抗联合伊匹木单抗一线治疗在至少随访61.3个月时显示较化疗更优的OS和颅内疗效结局。
- 作者认为这些结果进一步支持纳武利尤单抗联合伊匹木单抗作为转移性NSCLC的有效一线治疗,无论基线脑转移状态如何。
局限性
- 本文为事后探索性分析。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In CheckMate 227 Part 1, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) expression. Here, we report post hoc exploratory systemic and intracranial efficacy outcomes and safety by baseline brain metastasis status at 5 years' minimum follow-up. METHODS: Treatment-naive adults with stage IV or recurrent NSCLC without EGFR or ALK alterations, including asymptomatic patients with treated brain metastases, were enrolled. Patients with tumor PD-L1 greater than or equal to 1% were randomized to nivolumab plus ipilimumab, nivolumab, or chemotherapy; patients with tumor PD-L1 less than 1% were randomized to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy groups. Assessments included OS, systemic and intracranial progression-free survival per blinded independent central review, new brain lesion development, and safety. Brain imaging was performed at baseline (all randomized patients) and approximately every 12 weeks thereafter (patients with baseline brain metastases only). RESULTS: Overall, 202 of 1739 randomized patients had baseline brain metastases (nivolumab plus ipilimumab: 68; chemotherapy: 66). At 61.3 months' minimum follow-up, nivolumab plus ipilimumab prolonged OS versus chemotherapy in patients with baseline brain metastases (hazard ratio = 0.63; 95% confidence interval: 0.43-0.92) and in those without (hazard ratio = 0.76; 95% confidence interval: 0.66-0.87). In patients with baseline brain metastases, 5-year systemic and intracranial progression-free survival rates were higher with nivolumab plus ipilimumab (12% and 16%, respectively) than chemotherapy (0% and 6%). Fewer patients with baseline brain metastases developed new brain lesions with nivolumab plus ipilimumab (4%) versus chemotherapy (20%). No new safety signals were observed. CONCLUSIONS: With all patients off immunotherapy for more than or equal to 3 years, nivolumab plus ipilimumab continued to provide a long-term, durable survival benefit in patients with or without brain metastases. Intracranial efficacy outcomes favored nivolumab plus ipilimumab versus chemotherapy. These results further support nivolumab plus ipilimumab as an efficacious first-line treatment for patients with metastatic NSCLC, regardless of baseline brain metastasis status.
引用
- Reck M, Ciuleanu TE, Lee JS, et al. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. J Thorac Oncol. 2023. PMID: 37146754. doi:10.1016/j.jtho.2023.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。